Skip to main content
. 2023 Feb 27;10:303–313. doi: 10.2147/JHC.S399135

Figure 1.

Figure 1

Flow diagram showing enrollment and exclusion of patients with advanced HCC who received regorafenib plus ICIs with or without TACE in a second-line setting.

Abbreviations: HCC, hepatocellular carcinoma; ICIs, immune checkpoint inhibitors; TACE, transarterial chemoembolization.